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Abstract
Background: Glioblastoma multiforme (GBM) represent the most aggressive brain tumor with a median overall
survival of about 12-15 months. Over 90% of GBM tumors have recently been shown to be infected with human
cytomegalovirus (HCMV). In this case-control study, we evaluated whether there was an association between the
grade of HCMV infection and long-term survival (> 18 months) in GBM patients.
Material and methods: Brain tumor tissue sections from consecutive GBMs patients who survived more than 18
months (n = 40), and an equal number of GBM patients, matched to date of diagnosis and surgery, operated at
Karolinska University Hospital in 2000-2005 were selected. HCMV infection grade was determined by estimation of
the number of HCMV positive cells (scored negative or grade 1-4) in tumor tissue specimens. Using Chi-Square test
and logistic regression analysis, we analyzed whether there was an association between long-term survival and
HCMV low-grade infection or other clinical parameters known to be associated with prolonged survival of GBM
patients; age under 50 years, radical surgery or low recursive partition analysis (RPA) subclass.
Results: HCMV infection was detected in tumor samples from 79 of 80 patients (99%). Among patients surviving >
18 months, HCMV infection grade 1 in the GBM tumor was predominant. A low grade HCMV infection was found
in 19 patients, of these 16 survived > 18 months. Thus, 16 of 40 (40%) GBM patients who lived > 18 months had
low-grade HCMV infection while only 3 of 40 (8%) GBM patients who lived < 18 months did (p .0006, Chi-Square
test). Multiple logistic regression analyses yielded an odds ratio estimate of 6.604 with 95% confidence interval
(1.36-32.1) (p .019) for low grade HCMV after adjustment for RPA class III and IV, radical surgery, age and gamma
knife treatment.
Conclusion: In conclusion, we found that low-grade HCMV infection was strongly associated with long-term
survival in GBM patients.
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Introduction
Glioblastoma multiforme grade IV (GBM) is the most
aggressive and common brain tumor in humans. In
Sweden, with a population of 9 million, there are
approximately 300 new GBM cases per year [1]. Histolo-
gically, GBM is characterized by the presence of necrotic
areas in the brain tissue surrounded by anaplastic cells
and hyperplastic blood vessels, and a disparate genetic
signature, which illustrates the heterogeneity of this
tumor [2,3]. Current treatments such as surgical resec-
tion, radiation, and chemotherapy are relatively ineffec-
tive due to the aggressive nature of GBM. Despite
increasing molecular knowledge of GBM tumors, few
new therapeutic strategies have been offered these
patients during the past decades and these patients still
have a poor prognosis with a median survival of 12-15
months [4]. Recent studies have reported the presence
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in 90-100% of GBM tumors [5-7].
HCMV belongs to the herpesviridea family and main-
tains latency in pre-monocytic cells after a primary
infection [8]. Viral reactivation can occur when latently
infected monocytes undergo differentiation to macro-
phages or dendritic cells, which involves stimulation
with inflammatory cytokines [9,10]. Thus, it is possible
that the inflammatory environment in the glioblastoma
tumor triggers reactivation of latent HCMV.
Although there is compelling evidence that the
HCMV protein US28 may be oncogenic, this virus has
not been considered to be oncogenic. Rather, HCMV
proteins confer a variety of biological functions that
potentially affect tumor biology and contribute to cancer
progression. HCMV proteins for example interact with
p53, Rb and PTEN and influence cell-cycle regulation,
induce chromosomal aberrations, cellular differentiation,
migration, angiogenesis and confer immune evasion
mechanisms [11-16]. Recent studies have demonstrated
that HCMV-US28 induces cyclo-oxygenase-2 (COX2)
expression, production of vascular endothelial growth
factor (VEGF) and tumor formation in vivo, via activa-
tion of nuclear factor kappa B (NF-kB), STAT3 phos-
phorylation and accumulation of beta cathenin in the
cell nucleus. Furthermore, we found that phosphorylated
STAT-3 was correlated with poor survival of GBM
patients [17-19]. Thus, this virus may either be an epi-
phenomenon of glioblastomas or may through its
sophisticated strategies that affect tumor biology and
provide immune evasion strategies contribute to cancer
progression. We recently demonstrated that targeting
HCMV infection in medulloblastoma tumors with an
anti-viral drug and a COX-2 inhibitor prevented tumor
growth by 72% in an animal model [20]. These observa-
tions suggest that HCMV may contribute to the tumor-
genesis of medulloblatsoma tumors, and that the virus
may be a novel target for cancer therapy. We hypothe-
sized that if the virus affects tumor progression, a low
grade HCMV infection in glioblastomas may be asso-
ciated with longer patient survival. In this case-control
study, we investigated if the grade of HCMV infection
in GBM tumors was associated with survival over 18
months.
Materials and methods
Patient samples
We evaluated the association between HCMV infection
grades at diagnosis and survival time in a case-control
cohort of patients with GBMs operated at Karolinska
University Hospital between 2000 and 2005. Paraffin
embedded brain tumor samples from first surgery of all
available consecutive patients who lived > 18 months
were collected and similar number of samples obtained
from GBM patients matched to date of first surgery and
diagnosis were included (Table 1). All patients had
World Health Organization (WHO) grade IV GBM and
received standard treatment. At least two experienced
neuropathologists (mainly AO and JW) independently
confirmed the diagnosis. Classification of patients was
performed according to the adapted European Organiza-
tion for Research and Treatment of Cancer recursive
partition analysis classification [21]. The study was
approved by the Ethics Committee at Karolinska Institu-
tet, Stockholm, Sweden (2008/628-31/2).
Immunohistochemistry and in Situ Hybridization
Paraffin embedded brain tumor tissue sections (6 μm)
were analyzed by sensitive immunostaining as previously
described [5]. Briefly, tissue sections were de-waxed in
Xylene and rehydrated in alcohol series. After post fixation
in 4% neutral buffered formalin (Pharmacy at Karolinska
University Hospital, Sweden), sections were enzymatic
treated by pepsin (Sigma-Aldrich AB, Stockholm, Sweden)
in 3 min at 37°C and treated in Citra buffer pH 7.6 (Bio-
genex, San Ramon, CA). Endogenous peroxidase activity
was blocked with 3% H2O2, biotin and avidin were blocked
with the Biotin/Avidin Blocking kit (DakoCytomation,
Denmark) and Fc receptors were blocked with Fc receptor
blocker (Innovex Sciences, US). The following primary
antibodies were used: anti-HCMV-IEA (reacts with an
immediate early non-structural antigen of 68-72 kDa),
HCMV late antigen (LA, reacts with a late protein of 47-
55 kD) (both IgG2a, Chemicon International, US). Sam-
ples were stained with antibodies against smooth muscle
cell alpha actin (IgG2a, Biogenex) or no primary antibody
(only dilution buffer) served as controls. Colorimetric
determination was performed with a three-step horserad-
ish peroxidase detection system (BioGenex) with the chro-
mogen diaminobenzidine (DAB) (Innovex Sciences, US).
AR (scientist) and AO (neuropathologist) examined the
specimens; neither had access to the clinical records of the
patients at the time of grading.
HCMV Infection was graded according to the esti-
mated percentage of infected cells in the specimen:
negative or grade 1, < 25%; grade 2, ≥ 25% to 50%;
grade 3, ≥ 50% to 75%; and grade 4, > 75%. Proliferation
of tumor cells (MIB index, Ki-67), p53 mutation, mito-
sis, glial fibrillary acidic protein (GFAP), were detected
with automated immunohistochemical staining protocols
at our hospital.
Tissue sections were examined for HCMV-DNA by in
situ hybridization protocols as described previously [5].
Briefly, slides were pretreated as described above for
immunohistochemistry. After pretreatment in Citrate
buffer, slides were de-hydrated in alcohol series and air
dried before adding HCMV-DNA total genome fluores-
cein labeled probes (Zymed Labs, South San Francisco,
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negative (nonspecific DNA) fluorescein labeled probes
were used as positive and negative probes, respectively,
(both control probes were from Zymed Labs, South San
Francisco, CA). Tissue sections were denatured at 90°C
for 10 minutes and hybridized at 37°C over night using a
Misha thermocycler (DakoCytomation, Denmark). Endo-
genous peroxidase activity and FC receptors were blocked
as was described above for immunohistochemistry. Fluor-
escein labeled probe was detected by using mouse anti -
fluorescein antibodies (BioSite, Stockholm, Sweden),
horseradish peroxidase labeled goat anti mouse antibodies
(BioGenex) and DAB (Innovex Sciences).
Statistical analysis
All statistical analyses were performed by a medical sta-
tistician (Fredrik Hansson, Commitum, Lund, Sweden).
Chi-square test and logistic regression analysis was used
to assess the association between survival > 18 months
and HCMV infection while adjusting for known prog-
nostic factors such as age, RPA class and extent of
resection (and use of gamma knife). Power calculations
were used to estimate the number of patients that
should be included in the study. Calculating with a
power of 80% with an alpha level of 5% and a follow-up
time of 3 years, using a formula from Lachin JM. [22],
the required number of patients was 70. Pv a l u e s<. 0 5
were considered significant.
Results
HCMV infection level is associated with overall
survival in GBM patients
HCMV-IEA was detected in 79 (99%) of 80 tumor sam-
ples obtained from GBM patients, and HCMV-LA in 76
(95%) of 80 samples. HCMV proteins were detected in
tumor cells but not in surrounding non-tumor cells
(Figure 1). HCMV infection was confirmed by in situ
hybridization in 7 samples (one negative and 6 HCMV
positive). HCMV DNA was present in all HCMV-posi-
tive samples (Figure 1) but not in the HCMV-negative
sample.
HCMV infection grade was determined by estimation
of the number of HCMV positive cells and scored as
grade 1-4 depending on the estimated percentage of
positive cells in tumor tissue specimens (grade 1; < 25%,
grade 2; ≤ 25%-50%, grade 3; ≤ 50%-75% and grade 4; >
75%). To examine the influence of the HCMV infection
grade on survival, two patient populations; long-term
survivors (> 18 months (n = 40)) and an equal number
of patients that survived ≤ 18 months (n = 40) matched
to date of first surgery and diagnosis for HCMV infec-
tion grade (Table 1), were analyzed. In the cohort of
patients who lived > 18 months, 40% of the patients
were negative or had grade 1 HCMV-IE infection and
median OS for these was 42.5 months (n = 16). 10% of
the patients had grade 2 and Median OS was 25.5
months (n = 4), 15% of patients had grade 3 and median
O Sw a s2 5m o n t h s( n=6 ) ,a n d3 5 %o fp a t i e n t sh a d e
grade 4 and median OS was 26 months (n = 14). Thus,
survival > 18 months does not clearly change as a func-
tion of grade; there seems to be a threshold level for the
significance of HCMV for survival. It was due to this
that the subsequent dichotomization to negative to
grade 1 vs grade 2-4 were used. In the cohort of patients
that survived ≤ 18 months; 8% and 20% had grade 1 and
2 HCMV-IE infection (n = 3 and n = 8) respectively
while 25% and 47.5% had grade 3 and grade 4 infection
(n = 10 and n = 19), respectively. In the cohort of GBM
patients that survived > 18 months, 16 of 40 patients
(40%) had low-grade HCMV-IEA infection. Among
patients surviving ≤ 1 8m o n t h so n l y3o f4 0( 8 % )h a d
Table 1 Patients’ characteristics
Characteristics Case control cohorts
Patients
surviving
Patients
surviving
> 18 months
(n = 40)
≤ 18 months
(n = 40)
(2000-2005) (2000-2005)
Age (years)
<5 0 12(30%) 9 (23%)
≥ 50 28(70%) 31(77%)
Gender
Male 24(60%) 24(60%)
Female 16(40%) 16(40%)
RPA class
III-IV 28(70%)* 10(25%)*
V-VI 12(30%) 30(75%)
Extent of surgery
Partial 3 (7.5%) 9 (22.5%)
Radical 37(92.5%)# 31(77.5%)#
Gammaknife
No 28(70%) 35(87.5%)
Yes 12(30%) 5 (12.5%)
RT + Temozolomide
No 32(80%) 39(97%)
yes 8 (2%) 1 (3%)
RT + adjuvant chemotherapy
No 17(42%) 21(52%)
Yes 23(58%) 19(48%)
Median follow-up time of those alive
at study closure (months)
48 (n = 15) 0 (n = 0)
A significant association was observed between RPA III-VI and number of
patients with overall survival > 18 months *: p < .0001. No significant
association was observed between radical surgery and longer patients survival
#: p .06 (Chi-Square test)
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infection was strongly associated with survival > 18
months (p .0006). Low-grade HCMV-LA infection was
detected in 19 of 40 (48%) tumors of patients that sur-
vived > 18 months and in 14 of 40 (35%) patients that
survived ≤ 18 months (p .26).
We also observed a significant association between
RPA subclass III-VI and overall survival > 18 months
(p < .0001, Chi-Square test), but not for radical surgery
(p. 0 6 , Chi-Square test), age, gender or treatment (Table
1). Next, we performed multiple logistic regression ana-
lysis in order to estimate odds ratio for survival > 18
months in patients with low-grade versus moderate to
high grade-HCMV infection and for other prognostic
factors important for survival of GBM patients (age,
extent of resection, and RPA subclass). We found an
odds ratio of 6.604 (p .019, 95% CI, 1.4 to 32.1) for low
grade HCMV-IEA infection and odds ratio for RPA
class III and IV was; 8.2 (p .002, 95% CI, 2.1 to 31) in
patients with low-grade HCMV-IEA infection. We also
found an odds ratio of 9.5 (p. 0006, 95%CI, 2.6 to 34.5)
for RPA class III and IV in patients with low-grade
HCMV-LA infection. However, we did not observe an
association with extent of surgery, age, gender and
gamma knife treatment for overall survival > 18 months
(Table 2).
No differences were observed in the number of
patients with either no or low or moderate to high
grade HCMV infection in regards to different therapies,
except for gamma knife treatment (Table 3). In patients
with no or low-grade HCMV-IEA infection, 7 (37%) of
19 patients had received gamma knife treatment (6
patients survived > 18 months, one patient survived ≤
18 months) as compared to 10 (16.4%) of 61 patients
with moderate to high-grade HCMV-IEA infection (6
patients survived > 18 months, 4 patients survived ≤ 18
months, Table 3).
Phenotypic characterization of GBMs
All phenotypic characterizations of other factors exam-
ined for diagnostic purpose; p53, GFAP, MIB-index and
mitosis in tissue sections were performed at the pathol-
ogy department in our hospital. In patients that survived
> 18 months, p53 mutations were found in 8 of 12
(67%) samples with moderate to high-grade HCMV-IEA
infection as compared with 4 of 13 (31%) in patients
with no or low-grade infection. p53 mutation was
detected in 7 of 9 (78%) patients with moderate to high-
grade HCMV-LA infection and in 5 of 16 (31%) with no
or low-grade infection.
In patients with overall survival ≤ 18 months, p53
mutation was detected in 5 of 19 (26%) patients with
moderate to high-grade HCMV-IEA infection and in 1/
3 (30%) with no or low-grade infection. In patients with
moderate to high-grade HCMV-LA infection, p53 muta-
tion was detected in 5/11 (45%) of patients as compared
t o1o f1 1( 9 % )p a t i e n t sw i t hn oo rl o w - g r a d eH C M V -
LA infection.
While no association between p53 mutations was
observed for HCMV IEA, we observed a significant
association between HCMV late protein expression and
p53 mutations (overall survival > 18 months; p .026)
The extent of mitosis and MIB-index did not differ sig-
nificantly between the two groups. All (n = 71) exam-
ined GBM specimens were positive for GFAP.
Discussion
The etiology of GBM is unknown and the prognosis for
G B Mp a t i e n t si ss t i l lp o o rd e s p i t er e c e n ta d v a n c e si n
medical treatment with temozolomide and radiotherapy
[23,24]. In our study, we demonstrate a strong associa-
tion between HCMV infection grade and overall survi-
val. In the cohort of GBM patients that survived > 18
months, 40% had no or low-grade HCMV-IEA infection
as compared with 8% of patients with overall survival ≤
18 months. Young age (< 50 years) and good neurologic
function have been reported to be important prognostic
factors in GBM patients. In our study, we observed a
significant association between no or low-grade HCMV-
IEA infection (p .0006) and RPA subclass III-VI (p<
.0001) and survival > 18 months. Further regression ana-
lyses of factors influencing survival of patients with low-
grade versus high grade-HCMV infection in GBM tis-
sues included, age, extent of resection, gender and RPA
subclass. We found an odds ratio of 6.6 for low-grade
HCMV infection and 8.2 for RPA subclass III and IV
(p. 0 1 9a n dp. 0 0 2 , respectively). However, no
Figure 1 Detection of HCMV expression by immunohisto-
chemistry. Low-grade HCMV-IEA infection (A, B), low-grade
HCMV-LA infection (C, D) and SMC-alpha actin (E) in tissue sections
obtained from a GBM patient. Moderate to high-grade HCMV-IEA (F,
G), moderate to high grade HCMV-LA (H, I) and SMC-alpha actin (J)
in GBM. Bar, 50 μm Detection of HCMV DNA by in situ hybridization
(K, L), Alu; positive control (M, P) and negative control (Q) in GBMs.
Bar, 50 μm.
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gery, age, gender or gamma knife treatment (Table 2).
HCMV infection was detected exclusively in tumor
cells and endothelial cells in the tumor part, but not in
the non-tumor part of the tissue, which suggest that
HCMV infection is restricted to the tumor cells. HCMV
proteins may affect many central mechanisms in tumor
biology and confer immune evasion mechanisms. For
instance HCMV-IE72 and IE86 proteins interact with
p53 and Rb that result in enhanced cellular proliferation
[12,14]. In this study, we found that p53 mutation
was associated with HCMV-LA expression (p .026 in
patients surviving > 18 months), which implies a poten-
tial viral effect on p53. Interestingly, HCMV has been
shown in vitro to cause mutations, in particular in p53
in cells that are transformed by IE72, IE86 and adeno-
virus E1A proteins [16]. These and other HCMV pro-
teins also affect several additional pathways in the
cellular machinery linked to tumor biology, such as
cell cycle control, enhanced proliferation and migration
of the cells, stimulation of telomerase activity, indu-
ced expression of COX-2 and 5-lipoxygenase and
production of prostaglandin E2, leukotriene B4, and
accumulated beta cathenin with potential key functions
in HCMV induced oncogenesis or cancer progression
[12,15-17,25-29]. In collaboration with Smit’s group, we
recently described an additional potential oncomodula-
tory role of HCMV US28, which is a viral G protein-
coupled receptor encoded by HCMV (18). HCMV-US28
expression in the cells stimulated activation of STAT-3
and secretion of IL-6 and VGEF that led to enhanced
proliferation and angiogenesis of HCMV infected cells.
Interestingly, HCMV-US28 was found to be expressed
in GBM tissue sections and GBM patients that had high
grade phosphorylated STAT-3 (pSTAT-3) in their
tumors had shorter time to tumor progression and over-
all survival (18). Interestingly, US28 expressing 3 T3-
cells injected into nude mice formed tumors [29]. Smit’s
and Lira’s groups established a transgenic mouse with
US28 expressed in the intestine [29]. These animals
developed adenomas and adenocarcinomas, further pro-
viding evidence that HCMV US28 may be oncogenic
[29]. Furthermore, Soroceanu et al have recently demon-
strated expression of US28 in 60% of GBM specimens
Table 2 Odds Ratio Estimates for patients surviving > 18 months in patients with low-grade versus high grade-HCMV
infection in their tumors and prognostic factors important for GBM patients survival (Age, Extent of Resection, RPA
Subclass and gamma knife treatment) by Multiple Logistic regression analysis.
Characteristic HCMV-IEA HCMV-LA
95%
LCL
Odds
ratio
95%
UCL
P
value
95%
LCL
Odds
ratio
95%
UCL
P
value
HCMV infection: Non to Low-grade vs. moderate to
high-grade
1.359 6.604 32.094 .019* 0.425 1.264 3.758 .67
Age group: <50 vs ≧ 50 y 0.080 0.338 1.428 .142 0.081 0.339 1.412 .137
Gender Female vs Male 0.317 0.965 2.938 .95 0.335 0.962 2.763 94
Extent of surgery: Radical vs partial 0.404 2.489 15.348 .326 0.342 1.723 8.691 .50
RPA: III and IV vsV and VI 2.148 8.161 30.997 .002* 2.615 9.504 34.545 .0006*
Gammaknife vs. no Gammaknife treatment 0.326 1.339 5.505 .068 1.41 1.409 5.475 .62
*: considered significant, LCL (lower confidence interval), UCL (upper confidence interval)
Table 3 Therapy in patients whose tumors had low and high-grade infection with human cytomegalovirus Immediate-
early (IEA) and late antigen (LA)
Therapy Low-grade HCMV-IEA
(n = 19)
High-grade HCMV-IEA
(n = 61)
Low-grade HCMV-LA
(n = 33)
High-grade HCMV-LA
(n = 47)
Gamma knife 7 (37%) 10 (16.4%) 10 (30%) 7 (15%)
RT + adjuvant chemotherapy 7 (37%) 28 (46%) 14 (42%) 21 (45%)
Adjuvant chemotherapy 2 (11%) 7 (11%) 2 (6%) 7 (15%)
RT + Temozolomide 2 (11%) 8 (13%) 4 (12%) 6 (13%)
RT 1 (5.3%) 3 (5%) 1 (3%) 3 (6%)
RT + Lumostin 0 (0%) 1 (2%) 0 (0%) 1 (2%)
RT + IRESSA 0 (0%) 2 (3%) 2 (6%) 0 (0%)
Cortisone 0 (0%) 1 (2%) 1 (3%) 0 (0%)
Palliative therapy 0 (0%) 4 (7%) 1 (3%) 3 (6%)
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genic properties of US28 mediated by US28-CCL5 para-
c r i n es i g n a l i n gm a yc o n t r i b u t et og l i o m ap r o g r e s s i o n
[30].
A recent study by Dziurzynski et al showed that
HCMV infection in glioblastoma stem cells (gCSCs)
results in induction of viral IL-10 that activates HCMV-
IE1 in monocytes and affects polarization of macro-
phages toward a M2 phenotype of macrophages. The
authors claim that immunosuppressive M2 macrophages
in GBM patients may contribute to gliomagenesis via
induction of VEGF and enhanced angiogenesis, and
increase immunosuppression by production of TGF-beta
[31]. Both HCMV IL-10 andH C M V - U S 2 8s t i m u l a t e
activation of STAT-3 (pSTAT-3) and thereby link them
to tumorigenesis [32]. pSTAT-3 down regulates the
anti-tumor response, suppresses macrophage activation,
reduces NK cell and neutrophil cytotoxicity and impairs
dendritic cell function [33].
In this study, we demonstrate that low-grade HCMV
infection is strongly associated with long-term survival
in glioblastoma patients, and hence the level of HCMV
infection may provide a useful prognostic marker for
survival of glioblastoma patients. This observation also
implies that HCMV may be important in glioblastoma
progression, and that the virus may provide a target for
cancer therapy. In support of this hypothesis, we have
recently demonstrated that the growth of HCMV
infected human meduloblastoma xenografts can be
inhibited by therapies targeting HCMV. Treatment of
animals carrying HCMV positive human medulloblas-
toma xenografts with the anti-viral drug valganciclovir
and the COX-2 inhibitor Celecoxib (that also targets
HCMV replication) resulted in a 72% inhibition of
tumor growth without using chemotherapy [20].
In summary, our results suggest that low grade
HCMV infection in glioblastoma tumors is strongly
associated with longer survival of GBM patients. This
observation further supports the hypothesis that this
virus may play a pathogenetic role in GBM tumors
rather than representing an epiphenomenon. Targeting
HCMV with anti-viral drugs may affect the viral load in
the tumor and thereby prevent progressive disease. In
support of this statement, we have recently completed
the first clinical phase I/II trial on anti-viral therapy in
glioblastoma patients, which indicate improved overall
survival in patients receiving long-term treatment of
valganciclovir.
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